<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385658</url>
  </required_header>
  <id_info>
    <org_study_id>CXUO320BDE35</org_study_id>
    <nct_id>NCT00385658</nct_id>
  </id_info>
  <brief_title>Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome</brief_title>
  <official_title>A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will investigate the effects of the combination of fluvastatin and fenofibrate on
      dyslipidemia in comparison to the combination of simvastatin and ezetimibe.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High density lipoprotein cholesterol (HDL-C) measured at the end of each study period.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compared at the end of each treatment period:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients reaching target levels of low density lipoprotein cholesterol (LDL-C) &lt;100mg/dl</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients reaching target levels of non-HDL-C &lt;130mg/</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C/HDL-C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL subfractions in a subgroup of patients</measure>
  </secondary_outcome>
  <enrollment type="Actual">75</enrollment>
  <condition>Dyslipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin extended release, fenofibrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed combination simvastatin/ezetimibe</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent to participate in the study prior to any study procedures.

          -  Male or female subjects, age between 18-75 years inclusive.

          -  All women of child bearing potential must have a negative pregnancy test

          -  Metabolic Syndrome according to the International Diabetes Federation definition:

               -  Low plasma HDL-C (Men &lt; 40 mg/dl ; Women &lt; 50 mg/dl ).

               -  Elevated waist circumference (men ≥ 94 cm, women ≥ 80cm)

               -  And one or more of the following criteria:

                    -  Triglycerides ≥ 150 mg/d.l

                    -  Raised blood pressure (DBP ≥ 85 mmHg and/or SBP ≥ 130mmHg ) or treated
                       hypertension.

                    -  Fasting plasma glucose≥ 100mg/dl.

                    -  Previously diagnosed type 2 diabetes.

        Exclusion Criteria:

          -  Dyslipidemia secondary to other causes such as nephrotic syndrome, autoimmune disease.

          -  Type 1 diabetes.

          -  HbA1c &gt; 9.5%.

          -  Unexplained serum creatine phosphokinase &gt; 2 x Upper limit of normal.

          -  History of myocardial infarction and/or cerebral stroke and/or unstable angina
             pectoris.

          -  Known or suspected contraindications and warnings according to the country specific
             label for the investigational drugs.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma AG</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Pharma AG</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2457</url>
    <description>Results of study CXUO320BDE35 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>fluvastatin</keyword>
  <keyword>fenofibrate</keyword>
  <keyword>simvastatin</keyword>
  <keyword>ezetimibe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

